小米(01810.HK)投資證券研究機構及新媒體「市值風雲」
獨立第三方研究機構、新媒體 「市值風雲」宣佈完成億元級B輪融資,領投機構為洛克資本,深圳南山金融科技基金(國資)、小米集團(01810.HK)、新浪共同戰略入股。
據市值風雲方面透露,本輪融資完成後公司將正式進軍資本市場徵信評級業務和註冊制交易軟件領域,組建專業證券新聞記者團隊,並申請相應資質和牌照。
官網介紹,公司成立於2016年,是一家專注於上市公司獨立研究、金融大數據、行情與交易系統研發的信息科技公司,旗下擁有「市值風雲APP」內容平台,以及「吾股大數據」上市公司自動化評級系統與財務分析系統 。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.